Toth Financial Advisory Corp boosted its stake in DexCom, Inc. (NASDAQ:DXCM – Free Report) by 870.9% during the 1st quarter, according to its most recent Form 13F filing with the Securities and Exchange Commission (SEC). The fund owned 6,583 shares of the medical device company’s stock after acquiring an additional 5,905 shares during the period. Toth Financial Advisory Corp’s holdings in DexCom were worth $913,000 at the end of the most recent quarter.
Other institutional investors have also added to or reduced their stakes in the company. Cary Street Partners Investment Advisory LLC raised its position in shares of DexCom by 11.1% during the third quarter. Cary Street Partners Investment Advisory LLC now owns 1,153 shares of the medical device company’s stock worth $108,000 after purchasing an additional 115 shares during the period. CX Institutional acquired a new position in shares of DexCom during the fourth quarter worth approximately $286,000. Bank of New Hampshire acquired a new position in shares of DexCom during the first quarter worth approximately $1,508,000. abrdn plc raised its position in shares of DexCom by 21.1% during the fourth quarter. abrdn plc now owns 380,535 shares of the medical device company’s stock worth $47,221,000 after purchasing an additional 66,348 shares during the period. Finally, Cerity Partners LLC raised its position in shares of DexCom by 5,791.0% during the fourth quarter. Cerity Partners LLC now owns 463,973 shares of the medical device company’s stock worth $57,574,000 after purchasing an additional 456,097 shares during the period. 97.75% of the stock is currently owned by institutional investors.
Insider Transactions at DexCom
In other news, EVP Michael Jon Brown sold 659 shares of the stock in a transaction on Friday, June 28th. The stock was sold at an average price of $114.29, for a total transaction of $75,317.11. Following the completion of the transaction, the executive vice president now owns 66,901 shares in the company, valued at approximately $7,646,115.29. The transaction was disclosed in a filing with the Securities & Exchange Commission, which can be accessed through this hyperlink. In related news, EVP Michael Jon Brown sold 659 shares of the stock in a transaction dated Friday, June 28th. The stock was sold at an average price of $114.29, for a total transaction of $75,317.11. Following the sale, the executive vice president now owns 66,901 shares of the company’s stock, valued at approximately $7,646,115.29. The sale was disclosed in a legal filing with the Securities & Exchange Commission, which is accessible through the SEC website. Also, EVP Sadie Stern sold 427 shares of the stock in a transaction dated Monday, June 10th. The stock was sold at an average price of $115.05, for a total value of $49,126.35. Following the sale, the executive vice president now directly owns 75,877 shares in the company, valued at approximately $8,729,648.85. The disclosure for this sale can be found here. In the last 90 days, insiders sold 55,735 shares of company stock worth $7,619,347. 0.30% of the stock is owned by company insiders.
Analysts Set New Price Targets
Get Our Latest Stock Report on DexCom
DexCom Stock Down 1.0 %
Shares of NASDAQ:DXCM opened at $113.38 on Friday. The company has a debt-to-equity ratio of 1.08, a current ratio of 2.90 and a quick ratio of 2.53. The company has a market capitalization of $45.09 billion, a PE ratio of 73.15, a price-to-earnings-growth ratio of 2.77 and a beta of 1.22. DexCom, Inc. has a 1 year low of $74.75 and a 1 year high of $142.00. The business has a fifty day moving average price of $123.14 and a two-hundred day moving average price of $125.70.
DexCom (NASDAQ:DXCM – Get Free Report) last posted its quarterly earnings results on Thursday, April 25th. The medical device company reported $0.32 earnings per share for the quarter, topping the consensus estimate of $0.27 by $0.05. The company had revenue of $921.00 million during the quarter, compared to the consensus estimate of $911.20 million. DexCom had a return on equity of 31.01% and a net margin of 16.82%. Analysts forecast that DexCom, Inc. will post 1.78 earnings per share for the current year.
About DexCom
DexCom, Inc, a medical device company, focuses on the design, development, and commercialization of continuous glucose monitoring (CGM) systems in the United States and internationally. The company provides its systems for use by people with diabetes, as well as for use by healthcare providers. Its products include Dexcom G6 and Dexcom G7, integrated CGM systems for diabetes management; Dexcom Share, a remote monitoring system; Dexcom Real-Time API, which enables authorized third-party software developers to integrate real-time CGM data into their digital health apps and devices; and Dexcom ONE, that is designed to replace finger stick blood glucose testing for diabetes treatment decisions.
Further Reading
- Five stocks we like better than DexCom
- How to Invest in Tech Stocks and Top Tech Stocks to Consider
- Upwork Stock’s Outlook: Numbers Solid Despite Gen-AI Challenges
- How Technical Indicators Can Help You Find Oversold Stocks
- What’s Behind Walgreens Stock Plunge: What Investors Can Do Next
- Where to Find Earnings Call Transcripts
- MarketBeat Week in Review – 6/24 – 6/28
Receive News & Ratings for DexCom Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for DexCom and related companies with MarketBeat.com's FREE daily email newsletter.